Form 4 Pacific Biosciences of California: William Meyer (Officer) For: 17 November By Investing.com
This article reports on a Form 4 filing for Pacific Biosciences of California (PACB), indicating an insider transaction by Officer William Meyer on November 17th. The article provides the title of the filing and mentions that PACB's stock price experienced a -3.83% change. Beyond this, the content primarily consists of navigation and market data, typical of a financial news portal.
Form 4 Pacific Biosciences of California: William Meyer (Officer) For: 17 November
This article reports on a Form 4 filing for William Meyer, an officer at Pacific Biosciences of California (PACB), pertaining to transactions on November 17. The filing is an official notification of changes in beneficial ownership of securities. The article provides the title of the filing and mentions the associated stock symbol PACB.
Director Kathy Palmer Ordonez proposes selling 18,595 Pacific Biosciences (PACB) shares.
Pacific Biosciences of California (PACB) director Kathy Palmer Ordonez has filed a Form 144, proposing to sell 18,595 common shares with an approximate sale date of November 17, 2026, and an aggregate market value of $33,093.52. The shares were acquired through restricted stock vesting in February 2022 for services rendered. The broker for the proposed sale is Morgan Stanley Smith Barney LLC.
2026 PacBio SMRT Grant offers PCR free sequencing opportunity, Pacific Biosciences of California announces
Pacific Biosciences of California has launched its 2026 PacBio SMRT Grant, inviting researchers to apply for a project using PCR-free targeted HiFi sequencing technology. This initiative will fund 24 to 96 sample projects, aiming to advance research into complex genomic regions using the company's PureTarget sequencing method. Additionally, PacBio previously offered the 2026 PacBio Fiber-seq SMRT Grant for plant and animal research, reinforcing its commitment to expanding access to advanced sequencing technologies.
PacBio to Participate in the Piper Sandler 38th Annual Healthcare Conference
PacBio announced that its management will participate in a fireside chat at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026, at 9:30 AM ET. A live webcast and replay of the event will be available on the company's investors page. PacBio is a leading developer of high-quality, highly accurate sequencing solutions for various research applications.
Weekly Recap: Stock sale agreement and UBS lowers price target
Pacific Biosciences of California, Inc. (PACB) has agreed to sell up to $100 million in common stock through Allen & Company, which could earn commissions up to 3%. Concurrently, UBS maintained its Neutral rating on PACB but reduced its price target from $3.05 to $2.70.
Pacific Biosciences of California team achieves 192.4 Gb HiFi human genome data milestone
Pacific Biosciences of California announced a new milestone: researchers at Centre de recherche Azrieli du CHU Sainte-Justine generated 192.4 gigabases of HiFi data from a human whole-genome sequencing library in 24 hours. This achievement used the SPRQ-Nx chemistry on the Revio platform, highlighting advancements in sequencing throughput and speed. The company is also expanding its genomics tools with a new SMRT Grant for plant and animal research and a WGS Variant Pipeline.
Wilson Sonsini Advises PacBio on $100 Million At-the-Market Stock Offering
Wilson Sonsini Goodrich & Rosati advised Pacific Biosciences of California, Inc. (PacBio) on its sales agreement with Allen & Company LLC for an at-the-market stock offering of up to $100 million. PacBio, a developer of advanced sequencing technologies, plans to use the proceeds for research and development, working capital, and general corporate purposes. The offering allows PacBio to sell shares of its common stock through Allen & Company LLC.
Pacific Biosciences Launches $100 Million At-The-Market Stock Offering
Pacific Biosciences (PACB) has initiated an at-the-market program to offer up to $100 million of its common stock through a sales agreement with Allen & Company. This program provides the company with flexibility to raise capital over time, with Allen & Company acting as the sales agent and receiving a commission of up to 3% of the gross proceeds. The agreement was signed on November 10, 2026, and allows the company to set the timing and amount of sales.
Goldman Sachs reports a passive stake above 5% in Pacific Biosciences (PACB).
The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, have reported a beneficial ownership of 23,515,936 shares, or 7.6%, in Pacific Biosciences of California, Inc. (PACB). This passive investment disclosure was made via a SCHEDULE 13G SEC filing, indicating shared voting and disposition power over the reported shares. The filing details show that both the parent and subsidiary levels hold the same reported position.
Pacific Biosciences of California, Inc. 2026 Q3 - Results - Earnings Call Presentation
Pacific Biosciences of California, Inc. published their Q3 2026 earnings call presentation, reporting an EPS of -$0.11 which beat estimates by $0.02, and revenue of $40.56M, a 5.52% year-over-year increase, beating estimates by $1.10M. The article provides access to the slide deck from the earnings call.
PacBio (PACB) Q3 2026 Earnings Call: SPRQ-Nx-Einführung und eingeengte Umsatzprognose
PacBio reported a 6% increase in Q3 2026 revenue to $40.6 million, driven by strong instrument sales and growth in EMEA, despite a dip in gross profit due to higher memory costs. The company narrowed its full-year revenue forecast to $155-$160 million and reduced operating expense expectations through restructuring. PacBio remains committed to its SPRQ-Nx rollout and aims for cash flow breakeven by 2028.
Pacific Biosciences of California Inc (PACB) (Q3 2026) Earnings Call Highlights: Revenue Grows ...
Pacific Biosciences of California Inc (PACB) reported its Q3 2026 earnings, showing total revenue of $40.6 million, a 6% increase year-over-year. Instrument revenue grew 16%, while consumables revenue saw a slight decline. The company narrowed its full-year revenue guidance to $155-$160 million and expects to achieve cash flow breakeven by 2028.
What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call
Pacific Biosciences (PACB) reported 6% revenue growth in Q3 2026, reaching $40.6 million, driven by the adoption of its SPRQ-Nx sequencing chemistry and increased instrument sales. Despite a decline in consumables revenue and academic funding constraints, the company is expanding its clinical and AI programs, with clinical business now exceeding 20% of its total revenue. PacBio narrowed its full-year revenue outlook to $155 million-$160 million and expects to achieve cash flow breakeven in 2028.
Pacific Biosciences Reports $90.9M Net Loss Over First Nine Months of 2026 with Q3 Revenue Growth
Pacific Biosciences of California, Inc. (NASDAQ:PACB) reported a net loss of $90.9 million for the first nine months of 2026, a significant improvement from the $506 million loss in the same period of 2025. The company saw Q3 2026 total revenue increase to $40.56 million from $38.44 million in Q3 2025, driven by product sales and service revenue. Despite ongoing operating losses, gross profit for the nine-month period also increased.
What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call
Pacific Biosciences of California (PacBio) reported a 6% revenue increase in Q3 2026, reaching $40.6 million, driven by customer adoption of its SPRQ-Nx sequencing chemistry. Despite growth in instrument sales and clinical/AI programs, consumables revenue declined year-over-year, and academic funding constraints impacted instrument purchases in the Americas. The company narrowed its full-year revenue outlook to $155 million to $160 million and expects to achieve cash flow breakeven in 2028.
Pacific Biosciences Q3 2026 Earnings Call Transcript
Pacific Biosciences reported a 6% year-over-year revenue increase to $40.6 million in Q3 2026, driven by strong Revio placements and the adoption of its SparkNext Chemistry. The company is strategically expanding into clinical genomics and AI, evidenced by partnerships with GeneDx and Verily Health, and has narrowed its full-year revenue guidance to $155 to $160 million while targeting cash flow breakeven by 2028. Management also discussed leadership changes and uneven capital purchasing trends impacting the Americas.
PacBio (NASDAQ:PACB) reports bullish Q3 2026
Pacific Biosciences of California (NASDAQ: PACB) reported Q3 2026 results that exceeded Wall Street's revenue expectations, with revenue increasing 5.5% year-on-year to $40.56 million and a non-GAAP loss of $0.11 per share, beating analyst estimates. The company's President and CEO, Mark Van Oene, highlighted new opportunities driven by technology investments like SPRQ-Nx, growing clinical adoption, and strategic collaborations in genomics and AI. While PacBio's revenue growth has been mediocre over the last five years, analysts expect an improvement with a 9.4% growth over the next 12 months, driven by newer products and services.
Pacific Biosciences stock ahead of November 4 results call
Pacific Biosciences (PACB) stock is gaining attention as the company prepares to announce its third-quarter 2026 financial results on November 4, following the U.S. market close. The webcast, scheduled for 4:30 p.m. Eastern Time, will provide investors with insights into revenue trends, demand for sequencing systems, margins, and management's outlook. Ahead of the call, the stock was trading at 2.17 euros on Lang & Schwarz.
PacBio (PACB) reports Q3: everything you need to know ahead of earnings
PacBio (PACB) is set to announce its Q3 earnings this Wednesday, with market expectations of a 2.3% year-on-year revenue growth, a turnaround from a previous decrease. The company has a history of missing Wall Street's revenue estimates. Competitors like Illumina and West Pharmaceutical Services have already reported Q3 results, offering some insight into the sector's performance.
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
Pacific Biosciences of California (PacBio) announced that it will release its financial results for the third quarter of 2026 after the close of market trading on Wednesday, November 4, 2026. Following the release, the company will host a conference call and webcast to discuss these results and provide a business update, which will be accessible via its investor relations website.
Pacific Biosciences of California, Inc. (PACB) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Pacific Biosciences of California, Inc. (PACB), showing average monthly price returns from 2016 to 2026. It notes PACB's current stock performance, which is down 8.45%, and announces its upcoming Q3 2026 earnings call on November 4, 2026.
Pacific Biosciences of California, Inc. (PACB) Seasonal returns chart
This article provides a seasonal returns chart for Pacific Biosciences of California, Inc. (PACB), showing the average monthly price return from 2016 to 2026. It also includes current stock information, indicating a recent decrease in price, and details about an upcoming earnings call.
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PacBio (PACB) is positioned for growth due to its advanced sequencing technologies, including HiFi long-read and Onso short-read platforms, and increasing clinical adoption. Despite mixed Q2 2026 results, which saw a miss on revenue expectations and a lowered 2026 guidance due to funding headwinds and slower SPRQ-Nx adoption, the company's market leadership and recurring consumables revenue provide support. Challenges persist with instrument demand and profitability, pushing the cash flow breakeven target to 2028.
PacBio schedules November 4 results for Pacific Biosciences stock
Pacific Biosciences (PacBio) is scheduled to report its third-quarter 2026 results on November 4, 2026, after market close. The company's second-quarter revenue of USD 39.01 million fell below analyst estimates, but consumables revenue saw a 6% increase year over year, driven by clinical demand, particularly in EMEA. Despite a cautious 2026 revenue guidance of USD 155-165 million and a revised cash-flow breakeven target for 2028, the upcoming report will be crucial for investors to assess the balance between growing clinical adoption and weaker instrument demand.
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PacBio (PACB) is a Zacks Rank #3 (Hold) company gaining from its proprietary HiFi long-read sequencing and the launch of its Onso short-read system, which strengthen its market leadership. Growing clinical adoption and an expanding installed base are expected to drive recurring consumables revenues, despite mixed Q2 2026 results and persistent funding headwinds that have led to revised guidance.
PacBio to Participate in Upcoming Investor Conferences
PacBio announced its participation in three upcoming investor conferences in November 2026. Management will hold a fireside chat at the UBS Global Healthcare Conference and the Stephens NASH26 Conference, and engage in 1x1 investor meetings at the Jefferies Global Healthcare Conference. Live webcasts of the fireside chats will be available on the company's investor page.
Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $2.5
Stephens has reiterated its Buy rating on Pacific Biosciences of California (PACB.US) and increased its target price for the stock to $2.5. This indicates a continued positive outlook from the firm regarding the company's future performance.
Stephens raises target for Pacific Biosciences stock to USD 2.50
Stephens has increased its price target for Pacific Biosciences (PACB) stock from USD 1.50 to USD 2.50, maintaining an "Overweight" rating. This adjustment comes as PacBio prepares to report its third-quarter 2026 financial results on November 4, 2026. The stock was trading at EUR 1.87 on October 24, 2026, and the company's Q2 revenue of USD 39.01 million fell short of the USD 42.90 million consensus estimate.
Cathie Wood-Led Ark Invest Sells PLTR, GOOG, SHOP Stocks — But Loads Up On PACB, FRNM And Other Biotech Firms
Cathie Wood's Ark Invest recently adjusted its portfolio, divesting shares in several technology and growth companies, including Palantir (PLTR), Alphabet (GOOG), Shopify (SHOP), and Cloudflare (NET). Concurrently, Ark significantly increased its holdings in biotechnology firms, primarily through the ARK Genomic Revolution ETF (ARKG), adding positions in Pacific Biosciences of California (PACB), Scribe Therapeutics (SCTX), and Freenome (FRNM). These adjustments reflect a strategic shift, trimming established tech names while expanding exposure to the biotech sector.
Pacific Biosciences of California, Inc. Estimates – NASDAQ:PACB
This page on TradingView provides financial actuals and analyst estimates for Pacific Biosciences of California, Inc. (NASDAQ: PACB). Users can explore reported financial data and compare it with average, high, and low estimates across various financial statements and valuation metrics. The platform also visualizes trends over time for the company's financial performance.
PACB Stock Eyes AI Genomics Momentum With Verily, TychoBio Deals
Pacific Biosciences of California Inc. (PACB) stock rose by 7.91% following news of strategic collaborations with Verily Health and TychoBio. These partnerships aim to integrate PacBio's long-read sequencing technology into AI-driven platforms for biomedical discovery, population genomics, and RNA therapy design for rare diseases. Despite significant operating losses, the company's strong liquidity and positioning in the high-growth AI/genomics sector are attracting momentum traders.
Barclays cuts target for Pacific Biosciences stock to USD 1.25
Barclays has lowered its price target for Pacific Biosciences (PACB) stock to USD 1.25 from USD 1.50, maintaining a "Strong Sell" rating. This new target is 36.87 percent below the Nasdaq price of USD 1.98 as of October 20, 2026. Pacific Biosciences is scheduled to report its third-quarter 2026 financial results on November 4, 2026.
Pacific Biosciences of California, Inc. (PACB) stock price, news, quote and history
This article provides a comprehensive overview of Pacific Biosciences of California, Inc. (PACB), including its current stock price, historical performance, and key financial data. It details the company's business in developing sequencing solutions, its market presence, and analyst ratings. The report also covers recent earnings trends and valuation measures, offering a snapshot of PACB's financial health and market position.
DNA sequencing and health data will be joined to help train AI
PacBio and Verily Health have announced a multi-year partnership to integrate long-read genomic sequencing with governed health data and AI workflows. This collaboration aims to create AI-ready clinico-genomic datasets by combining PacBio's HiFi sequencing with Verily Pre, facilitating biomedical discovery and the training of AI models. The initiative addresses the growing need for deeper, more contextual biological data to power advanced biomedical AI applications, particularly in areas like neurology, oncology, and rare diseases.
Pacific Biosciences stock falls 11.73 percent to USD 1.73 on October 16, 2026
Pacific Biosciences (PACB) stock dropped 11.73% to USD 1.73 on October 16, 2026, closing at 4:00 p.m. ET. This decline occurred despite Simply Wall St raising its fair value estimate to USD 2.40, while UBS maintained a "Neutral" rating with a lower price target of USD 1.35. The company is set to report its Q3 2026 results on November 4, 2026.
Six brokerages set USD 1.71 target for Pacific Biosciences stock
Six brokerages have set a consensus price target of USD 1.71 for Pacific Biosciences (PACB) stock, with an average rating of "Reduce." This target is 13.64 percent below the latest Nasdaq quote of USD 1.98. The company is scheduled to report its third-quarter 2026 financial results on November 4, 2026.
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Pacific Biosciences of California (PACB) closed down 2.93% in its latest trading session, underperforming the S&P 500, Dow, and Nasdaq. Despite this, the stock has climbed 52.99% over the past month. Investors are looking ahead to upcoming earnings, with an anticipated EPS of -$0.13 and revenue of $37.86 million, and the company currently holds a Zacks Rank of #3 (Hold).
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
PacBio (NASDAQ: PACB) announced it will hold its quarterly conference call to discuss its third-quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time. The call will be webcast and accessible on PacBio’s investor website. PacBio specializes in advanced sequencing solutions for life sciences research.
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
Pacific Biosciences of California (PacBio) has announced a collaboration with TychoBio, an AI-driven drug discovery company, to generate full-length RNA sequencing data for developing AI models. These models will focus on creating RNA therapies for rare diseases, initially targeting steric blocking antisense oligonucleotides (SBOs) with plans to expand to other RNA-targeting compounds. The partnership aims to leverage PacBio's HiFi and Kinnex sequencing technologies to build large datasets linking SBO designs to their transcriptome-wide effects, enhancing the precision and efficacy of AI-driven drug discovery for rare conditions.
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
PacBio has announced a collaboration with TychoBio to generate full-length RNA sequencing data for training AI models focused on developing RNA therapies for rare diseases. The partnership will initially concentrate on steric blocking antisense oligonucleotides (SBOs) and aims to expand to other RNA-targeting compounds, leveraging PacBio's HiFi and Kinnex long-read RNA sequencing technologies. This initiative highlights the growing intersection of advanced sequencing and AI in therapeutic research, with PacBio's platform enabling detailed analysis to identify promising drug candidates and improve patient outcomes.
PACB5949325 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the PACB5949325 bond issued by Pacific Biosciences of California, Inc. It outlines key facts such as the issuer, issue and maturity dates, face value, and minimum denomination. The bond has a fixed coupon rate of 1.50% paid semi-annually, with upcoming payout schedules detailed until its maturity in August 2029.
Weekly Recap: PACB Q2 results, narrowed guidance and TychoBio RNA AI
Pacific Biosciences of California (NASDAQ:PACB) reported its Q2 2026 financial results, including $39M in revenue and a GAAP loss of $0.14 per share, and narrowed its full-year revenue guidance to $155–$165M. The company also announced a partnership with TychoBio to generate over 10,000 full-length RNA datasets using PacBio's HiFi and Kinnex sequencing technologies to train AI for RNA therapeutic design. PACB held $236.9M in cash and investments at the end of June.
Form 144 Pacific Biosciences of California For: 11 October By Investing.com
This article reports on the filing of Form 144 for Pacific Biosciences of California (PACB) on October 11, 2026. Form 144 indicates an intent to sell restricted securities. The brief article, published by Investing.com, includes a link to the company's stock performance and general market data.
Form 144 Pacific Biosciences of California For: 11 October By Investing.com
This article announces the filing of Form 144 by Pacific Biosciences of California on October 11, 2026. The piece is brief, solely indicating the date of the filing for the company PACB, which saw a 1.30% increase.
Form 4 Pacific Biosciences of California For: 10 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Pacific Biosciences of California (PACB) on October 10. Form 4 filings are used to report changes in beneficial ownership of a company's securities by insiders. The article indicates a 1.30% increase for PACB.
Pacific Biosciences CFO reports $2.05m stock sale
James R Gibson II, CFO of Pacific Biosciences of California, Inc. (NASDAQ:PACB), sold company stock worth $2,056,921 on October 6, 2026, under a Rule 10b5-1 trading plan. Prior to the sale, he exercised options to acquire 500,000 shares for $590,000. Despite the recent stock decline, shares have surged 64% over the past year, while recent financial results indicated missed revenue forecasts and a revised full-year outlook.
Form 4 Pacific Biosciences of California For: 10 October By Investing.com
This article from Investing.com announces the filing of a Form 4 for Pacific Biosciences of California on October 10. The content primarily consists of navigational elements and market data, with the core information being the Form 4 filing.
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
Pacific Biosciences of California (PACB) stock fell 15.44% in its most recent trading session, underperforming the broader market. Despite this recent dip, the company's stock has seen a significant rise over the past month, and investors are anticipating its upcoming earnings report, with projections for EPS and revenue indicating a slight decline from the previous year's quarter. Analysts' estimate revisions and the company's Zacks Rank of #3 (Hold) suggest a cautious but not unfavorable outlook.
Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Maintains Target Price $1.25
Barclays has reiterated its Sell rating on Pacific Biosciences of California (PACB.US) and maintained its target price of $1.25. This indicates that the firm continues to have a negative outlook on the company's stock performance.